Prospectus Supplement
(To Prospectus dated August 8, 2019)
4,000,000 Depositary Shares
Each Representing a 1/400th Interest in a Share of 7.00%
Fixed-Rate Reset Non-Cumulative Perpetual Preferred Stock, Series E
We are offering 4,000,000 depositary shares, each representing a 1/400th ownership interest in a share of our 7.00% Fixed-Rate Reset Non-Cumulative Perpetual Preferred Stock, Series E, par value $1.00 per share (the “Series E Preferred Stock”), with a liquidation preference of $25 per depositary share (equivalent to $10,000 per share of Series E Preferred Stock). As a holder of depositary shares, you will be entitled to all proportional rights and preferences of the Series E Preferred Stock represented thereby (including dividend, voting, redemption, and liquidation rights). You must exercise any such rights through the depositary.
We will pay dividends on the Series E Preferred Stock, when, as, and if declared by our board of directors or a duly authorized committee of our board of directors, to the extent that we have lawfully available funds to pay dividends. If declared, dividends will accrue and be payable, quarterly in arrears, (i) from and including the date of original issuance to, but excluding, July 15, 2025 (the “First Reset Date”) at a rate of 7.00% per annum, on January 15, April 15, July 15 and October 15 of each year, commencing on October 15, 2020, and (ii) from and including July 15, 2025, during each reset period, at a rate per annum equal to the five-year treasury rate as of the most recent reset dividend determination date (as described elsewhere in this prospectus supplement) plus 6.675%, on January 15, April 15, July 15, and October 15 of each year, beginning on July 15, 2025, except in each case where such day is not a business day. Upon payment of any dividends on the Series E Preferred Stock, holders of depositary shares are expected to receive a proportionate payment.
Dividends on the Series E Preferred Stock will not be cumulative. If for any reason our board of directors or a duly authorized committee of our board of directors does not declare a dividend on the Series E Preferred Stock for any dividend period, that dividend will not accrue or be payable and we will have no obligation to pay dividends for that dividend period, whether or not dividends on the Series E Preferred Stock are declared for any future dividend period.
We may redeem the Series E Preferred Stock at our option, and subject to any required regulatory approval, (i) in whole or in part, from time to time, on any reset date on or after the First Reset Date at a redemption price equal to $10,000 per share (equivalent to $25 per depositary share), plus any declared and unpaid dividends, without accumulation of any undeclared and unpaid dividends, to, but excluding, the redemption date, or (ii) in whole but not in part, at any time within 90 days following a regulatory capital treatment event (as defined herein), including prior to the First Reset Date, at a redemption price equal to $10,000 per share (equivalent to $25 per depositary share), plus any declared and unpaid dividends, without accumulation of any undeclared and unpaid dividends, to, but excluding, the redemption date. If we redeem the Series E Preferred Stock, the depositary will redeem a proportionate number of depositary shares. Holders of depositary shares will not have the right to require the redemption or repurchase of the depositary shares.
We have filed an application to list the depositary shares on the Nasdaq Global Select Market under the symbol “HTLFP.” If the application is approved, trading of the depositary shares on Nasdaq is expected to begin within 30 days after the date of initial issuance of the depositary shares, and we will use our reasonable best efforts to maintain such listing so long as any of the depositary shares remain outstanding. Our common stock is listed on the Nasdaq Global Select Market and trades under the ticker symbol “HTLF.”
The Series E Preferred Stock will not have any voting rights, except as set forth under “Description of Preferred Stock—Voting” beginning on page S-
37.
Investing in the depositary shares involves risk. You should refer to “Risk Factors” beginning on page S-
18 of this prospectus supplement, on page
1 of the accompanying prospectus and in “Item 1A.” of our Annual Report on Form 10-K for the year ended December 31, 2019 and our Quarterly Report on Form 10-Q for the quarter ended March 31, 2020.
The depositary shares are not savings accounts, deposits, or other obligations of any bank and are not insured or guaranteed by the Federal Deposit Insurance Corporation (the “FDIC”) or any other governmental agency. The depositary shares are ineligible as collateral for a loan or extension of credit from Heartland Financial USA, Inc. or any of our subsidiaries. Neither the Securities and Exchange Commission (the “SEC”), any state securities commission, the FDIC, the Board of Governors of the Federal Reserve (the “Federal Reserve”), or any other regulatory body has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus supplement or the accompanying prospectus. Any representation to the contrary is a criminal offense.
Public offering price(1) | | | $25.00 | | | $100,000,000 |
Underwriting discounts and commissions(2) | | | $0.7875 | | | $3,150,000 |
Proceeds, before expenses, to us(3) | | | $24.2125 | | | $96,850,000 |
(1)
| Plus accrued dividends, if any, from the date of original issuance, which is expected to be June 26, 2020. |
(2)
| See “Underwriting” in this prospectus supplement for details regarding compensation to be received by the underwriters in connection with this offering. |
(3)
| Assumes no exercise of the underwriters’ over-allotment option, described below. |
The underwriters may exercise their option to purchase up to an additional 600,000 depositary shares from us, at the public offering price, less underwriting discounts, for 30 days after the date of this prospectus supplement, solely to cover over-allotments, if any.
The underwriters expect to deliver the depositary shares to purchasers in book-entry form through the facilities of The Depository Trust Company and its direct participants, including Euroclear Bank S.A./N.V., as operator of the Euroclear System (“Euroclear”), and Clearstream Banking, a societe anonyme (“Clearstream”), on or about June 26, 2020.
Joint Book-Running Managers
Raymond James | | | Keefe, Bruyette & Woods A Stifel Company | | | Wells Fargo Securities | | | D.A. Davidson & Co. | | | Piper Sandler |
The date of this prospectus supplement is June 19, 2020.